|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bose P, Brockton NT and Dort JC: Head and
neck cancer: From anatomy to biology. Int J Cancer. 133:2013–2023.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rothenberg SM and Ellisen LW: The
molecular pathogenesis of head and neck squamous cell carcinoma. J
Clin Invest. 122:1951–1957. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Leemans CR, Braakhuis BJ and Brakenhoff
RH: The molecular biology of head and neck cancer. Nat Rev Cancer.
11:9–22. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fakhry C and Gillison ML: Clinical
implications of human papillomavirus in head and neck cancers. J
Clin Oncol. 24:2606–2611. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang C, Liu XQ, Hou JS, Wang JN and Huang
HZ: Molecular mechanisms of chemoresistance in oral cancer. Chin J
Dent Res. 19:25–33. 2016.PubMed/NCBI
|
|
7
|
Brown JM and Attardi LD: The role of
apoptosis in cancer development and treatment response. Nat Rev
Cancer. 5:231–237. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mohammad RM, Muqbil I, Lowe L, Yedjou C,
Hsu HY, Lin LT, Siegelin MD, Fimognari C, Kumar NB, Dou QP, et al:
Broad targeting of resistance to apoptosis in cancer. Semin Cancer
Biol. 35 (Suppl):S78–S103. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ambrosini G, Adida C and Altieri DC: A
novel anti-apoptosis gene, survivin, expressed in cancer and
lymphoma. Nat Med. 3:917–921. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mita AC, Mita MM, Nawrocki ST and Giles
FJ: Survivin: Key regulator of mitosis and apoptosis and novel
target for cancer therapeutics. Clin Cancer Res. 14:5000–5005.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Desantis V, Saltarella I, Lamanuzzi A,
Mariggiò MA, Racanelli V, Vacca A and Frassanito MA: Autophagy: A
new mechanism of prosurvival and drug resistance in multiple
myeloma. Transl Oncol. 11:1350–1357. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yang ZJ, Chee CE, Huang S and Sinicrope
FA: Autophagy modulation for cancer therapy. Cancer Biol Ther.
11:169–176. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sannigrahi MK, Singh V, Sharma R, Panda NK
and Khullar M: Role of autophagy in head and neck cancer and
therapeutic resistance. Oral Dis. 21:283–291. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mizushima N: Autophagy: Process and
function. Genes Dev. 21:2861–2873. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Altieri DC: Survivin, versatile modulation
of cell division and apoptosis in cancer. Oncogene. 22:8581–8589.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jaiswal PK, Goel A and Mittal RD:
Survivin: A molecular biomarker in cancer. Indian J Med Res.
141:389–397. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Verdecia MA, Huang H, Dutil E, Kaiser DA,
Hunter T and Noel JP: Structure of the human anti-apoptotic protein
survivin reveals a dimeric arrangement. Nat Struct Biol. 7:602–608.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chantalat L, Skoufias DA, Kleman JP, Jung
B, Dideberg O and Margolis RL: Crystal structure of human survivin
reveals a bow tie-shaped dimer with two unusual alpha-helical
extensions. Mol Cell. 6:183–189. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Caldas H, Honsey LE and Altura RA:
Survivin 2alpha: A novel Survivin splice variant expressed in human
malignancies. Mol Cancer. 4:112005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mahotka C, Wenzel M, Springer E, Gabbert
HE and Gerharz CD: Survivin-deltaEx3 and survivin-2B: Two novel
splice variants of The apoptosis inhibitor survivin with different
antiapoptotic properties. Cancer Res. 59:6097–6102. 1999.PubMed/NCBI
|
|
21
|
Mahotka C, Liebmann J, Wenzel M, Suschek
CV, Schmitt M, Gabbert HE and Gerharz CD: Differential subcellular
localization of functionally divergent survivin splice variants.
Cell Death Differ. 9:1334–1342. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
De Maria S, Pannone G, Bufo P, Santoro A,
Serpico R, Metafora S, Rubini C, Pasquali D, Papagerakis SM,
Staibano S, et al: Survivin gene-expression and splicing isoforms
in oral squamous cell carcinoma. J Cancer Res Clin Oncol.
135:107–116. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fortugno P, Wall NR, Giodini A, O'Connor
DS, Plescia J, Padgett KM, Tognin S, Marchisio PC and Altieri DC:
Survivin exists in immunochemically distinct subcellular pools and
is involved in spindle microtubule function. J Cell Sci.
115:575–585. 2002.PubMed/NCBI
|
|
24
|
Altieri DC: New wirings in the survivin
networks. Oncogene. 27:6276–6284. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cheung CH, Huang CC, Tsai FY, Lee JY,
Cheng SM, Chang YC, Huang YC, Chen SH and Chang JY:
Survivin-biology and potential as a therapeutic target in oncology.
Onco Targets Ther. 6:1453–1462. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Altieri DC: Survivin, cancer networks and
pathway-directed drug discovery. Nat Rev Cancer. 8:61–70. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Vaira V, Lee CW, Goel HL, Bosari S,
Languino LR and Altieri DC: Regulation of survivin expression by
IGF-1/mTOR signaling. Oncogene. 26:2678–2684. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Aoki Y, Feldman GM and Tosato G:
Inhibition of STAT3 signaling induces apoptosis and decreases
survivin expression in primary effusion lymphoma. Blood.
101:1535–1542. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kanda N, Seno H, Konda Y, Marusawa H,
Kanai M, Nakajima T, Kawashima T, Nanakin A, Sawabu T, Uenoyama Y,
et al: STAT3 is constitutively activated and supports cell survival
in association with survivin expression in gastric cancer cells.
Oncogene. 23:4921–4929. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Gritsko T, Williams A, Turkson J, Kaneko
S, Bowman T, Huang M, Nam S, Eweis I, Diaz N, Sullivan D, et al:
Persistent activation of stat3 signaling induces survivin gene
expression and confers resistance to apoptosis in human breast
cancer cells. Clin Cancer Res. 12:11–9. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li W, Cao Y, Xu J, Wang Y, Li W, Wang Q,
Hu Z, Hao Y, Hu L, Sun Y, et al: YAP transcriptionally regulates
COX-2 expression and GCCSysm-4 (G-4), a dual YAP/COX-2 inhibitor,
overcomes drug resistance in colorectal cancer. J Exp Clin Cancer
Res. 36:1442017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Barrett RM, Osborne TP and Wheatley SP:
Phosphorylation of survivin at threonine 34 inhibits its mitotic
function and enhances its cytoprotective activity. Cell Cycle.
8:278–283. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Duckett CS, Nava VE, Gedrich RW, Clem RJ,
Van Dongen JL, Gilfillan MC, Shiels H, Hardwick JM and Thompson CB:
A conserved family of cellular genes related to the baculovirus iap
gene and encoding apoptosis inhibitors. EMBO J. 15:2685–2694. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Deveraux QL, Takahashi R, Salvesen GS and
Reed JC: X-linked IAP is a direct inhibitor of cell-death
proteases. Nature. 388:300–304. 1997. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
LaCasse EC, Baird S, Korneluk RG and
MacKenzie AE: The inhibitors of apoptosis (IAPs) and their emerging
role in cancer. Oncogene. 17:3247–3259. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li F, Ackermann EJ, Bennett CF, Rothermel
AL, Plescia J, Tognin S, Villa A, Marchisio PC and Altieri DC:
Pleiotropic cell-division defects and apoptosis induced by
interference with survivin function. Nat Cell Biol. 1:461–426.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Altieri DC: Targeting survivin in cancer.
Cancer Lett. 332:225–228. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Tamm I, Wang Y, Sausville E, Scudiero DA,
Vigna N, Oltersdorf T and Reed JC: IAP-family protein survivin
inhibits caspase activity and apoptosis induced by Fas (CD95), Bax,
caspases, and anticancer drugs. Cancer Res. 58:5315–5320.
1998.PubMed/NCBI
|
|
39
|
Croci DO, Cogno IS, Vittar NB, Salvatierra
E, Trajtenberg F, Podhajcer OL, Osinaga E, Rabinovich GA and
Rivarola VA: Silencing survivin gene expression promotes apoptosis
of human breast cancer cells through a caspase-independent pathway.
J Cell Biochem. 105:381–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ceballos-Cancino G, Espinosa M, Maldonado
V and Melendez-Zajgla J: Regulation of mitochondrial
Smac/DIABLO-selective release by survivin. Oncogene. 26:7569–7575.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Du C, Fang M, Li Y, Li L and Wang X: Smac,
a mitochondrial protein that promotes cytochrome c-dependent
caspase activation by eliminating IAP inhibition. Cell. 102:33–42.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Song Z, Yao X and Wu M: Direct interaction
between survivin and Smac/DIABLO is essential for the
anti-apoptotic activity of survivin during taxol-induced apoptosis.
J Biol Chem. 278:23130–23140. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ghosh JC, Dohi T, Kang BH and Altieri DC:
Hsp60 regulation of tumor cell apoptosis. J Biol Chem.
283:5188–5194. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Fortugno P, Beltrami E, Plescia J, Fontana
J, Pradhan D, Marchisio PC, Sessa WC and Altieri DC: Regulation of
survivin function by Hsp90. Proc Natl Acad Sci USA.
100:13791–13796. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Marx J: Autophagy: Is it cancer's friend
or foe. Science. 312:1160–1161. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Galluzzi L, Vicencio JM, Kepp O, Tasdemir
E, Maiuri MC and Kroemer G: To die or not to die: That is the
autophagic question. Curr Mol Med. 8:78–91. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Decuypere JP, Parys JB and Bultynck G:
Regulation of the autophagic bcl-2/Beclin 1 interaction. Cells.
1:284–312. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Bhutia SK, Dash R, Das SK, Azab B, Su ZZ,
Lee SG, Grant S, Yacoub A, Dent P, Curiel DT, et al: Mechanism of
autophagy to apoptosis switch triggered in prostate cancer cells by
antitumor cytokine melanoma differentiation-associated gene
7/interleukin-24. Cancer Res. 70:3667–3676. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Haller M, Hock AK, Giampazolias E, Oberst
A, Green DR, Debnath J, Ryan KM, Vousden KH and Tait SW:
Ubiquitination and proteasomal degradation of ATG12 regulates its
proapoptotic activity. Autophagy. 10:2269–2278. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Norman JM, Cohen GM and Bampton ET: The in
vitro cleavage of the hAtg proteins by cell death proteases.
Autophagy. 6:1042–1056. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Wu H, Che X, Zheng Q, Wu A, Pan K, Shao A,
Wu Q, Zhang J and Hong Y: Caspases: A molecular switch node in the
crosstalk between autophagy and apoptosis. Int J Biol Sci.
10:1072–1083. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Han J, Hou W, Goldstein LA, Stolz DB,
Watkins SC and Rabinowich H: A Complex between Atg7 and Caspase-9:
A novel mechanism of cross-regulation between autophagy and
apoptosis. J Biol Chem. 289:6485–6497. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Coumar MS, Tsai FY, Kanwar JR, Sarvagalla
S and Cheung CH: Treat cancers by targeting survivin: Just a dream
or future reality. Cancer Treat Rev. 39:802–811. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Niu TK, Cheng Y, Ren X and Yang JM:
Interaction of Beclin 1 with survivin regulates sensitivity of
human glioma cells to TRAIL-induced apoptosis. FEBS Lett.
584:3519–3524. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Roca H, Varsos ZS, Mizutani K and Pienta
KJ: CCL2, survivin and autophagy: New links with implications in
human cancer. Autophagy. 4:969–971. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Loberg RD, Day LL, Harwood J, Ying C, St
John LN, Giles R, Neeley CK and Pienta KJ: CCL2 is a potent
regulator of prostate cancer cell migration and proliferation.
Neoplasia. 8:578–586. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Minematsu T, Iwai M, Sugimoto K, Shirai N,
Nakahara T, Usui T and Kamimura H: Carrier-mediated uptake of
1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazolium
bromide (YM155 monobromide), a novel small-molecule survivin
suppressant, into human solid tumor and lymphoma cells. Drug Metab
Dispos. 37:619–628. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Cheng SM, Chang YC, Liu CY, Lee JY, Chan
HH, Kuo CW, Lin KY, Tsai SL, Chen SH, Li CF, et al: YM155
down-regulates survivin and XIAP, modulates autophagy and induces
autophagy-dependent DNA damage in breast cancer cells. Br J
Pharmacol. 172:214–234. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Khan Z, Khan AA, Yadav H, Prasad GBKS and
Bisen PS: Survivin, a molecular target for therapeutic
interventions in squamous cell carcinoma. Cell Mol Biol Lett.
22:82017. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Rong L, Hongyan Guo H and Liu K: The role
of survivin in oral squamous cell carcinoma. Biom Res. 29:780–783.
2018.
|
|
61
|
Lo Muzio L, Pannone G, Leonardi R,
Staibano S, Mignogna MD, De Rosa G, Kudo Y, Takata T and Altieri
DC: Survivin, a potential early predictor of tumor progression in
the oral mucosa. J Dent Res. 82:923–928. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Lo Muzio L, Pannone G, Staibano S,
Mignogna MD, Rubini C, Mariggiò MA, Procaccini M, Ferrari F, De
Rosa G and Altieri DC: Survivin expression in oral squamous cell
carcinoma. Br J Cancer. 89:2244–2248. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Lo Muzio L, Farina A, Rubini C, Pezzetti
F, Stabellini G, Laino G, Santarelli A, Pannone G, Bufo P, de Lillo
A and Carinci F: Survivin as prognostic factor in squamous cell
carcinoma of the oral cavity. Cancer Lett. 225:27–33. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Lo Muzio L, Staibano S, Pannone G,
Mignogna MD, Mariggiò A, Salvatore G, Chieffi P, Tramontano D, De
Rosa G and Altieri DC: Expression of the apoptosis inhibitor
survivin in aggressive squamous cell carcinoma. Exp Mol Pathol.
70:249–254. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Su L, Wang Y, Xiao M, Lin Y and Yu L:
Up-regulation of survivin in oral squamous cell carcinoma
correlates with poor prognosis and chemoresistance. Oral Surg Oral
Med Oral Pathol Oral Radiol Endod. 110:484–491. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Kim MJ, Lim KY, Kim JW, Nam IW, Lee JH and
Myoung H: Stage and mRNA expression of survivin in lymph node as
prognostic indicators in patients with oral squamous cell
carcinoma. Cancer Lett. 224:253–261. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Zhang M, Li J, Wang L, Tian Z, Zhang P, Xu
Q, Zhang C, Wei F and Chen W: Prognostic significance of p21, p27
and survivin protein expression in patients with oral squamous cell
carcinoma. Oncol Lett. 6:381–386. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Münscher A, Prochnow S, Gulati A, Sauter
G, Lörincz B, Blessmann M, Hanken H, Böttcher A and Clauditz TS:
Survivin expression in head and neck squamous cell carcinomas is
frequent and correlates with clinical parameters and treatment
outcomes. Clin Oral Investig. 23:361–367. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Xie S, Xu H, Shan X, Liu B, Wang K and Cai
Z: Clinicopathological and prognostic significance of survivin
expression in patients with oral squamous cell carcinoma: Evidence
from a meta-analysis. PLoS One. 10:e01165172015. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Engels K, Knauer SK, Metzler D, Simf C,
Struschka O, Bier C, Mann W, Kovács AF and Stauber RH: Dynamic
intracellular survivin in oral squamous cell carcinoma: Underlying
molecular mechanism and potential as an early prognostic marker. J
Pathol. 211:532–540. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Liu S, Shi L, Yang X, Ye D, Wang T, Dong
C, Guo W, Liao Y, Song H, Xu D, et al: Nuclear survivin promoted by
acetylation is associated with the aggressive phenotype of oral
squamous cell carcinoma. Cell Cycle. 16:894–902. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Troiano G, Guida A, Aquino G, Botti G,
Losito NS, Papagerakis S, Pedicillo MC, Ionna F, Longo F, Cantile
M, et al: Integrative histologic and bioinformatics analysis of
BIRC5/Survivin expression in oral squamous cell carcinoma. Int J
Mol Sci. 19(pii): E26642018. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Aguilera P, Malvehy J, Carrera C, Palou J,
Puig-Butillé JA, Alòs L, Badenas C and Puig S: Clinical and
histopathological characteristics between familial and sporadic
melanoma in Barcelona, Spain. J Clin Exp Dermatol Res.
5:2312014.PubMed/NCBI
|
|
74
|
Lyu H, Huang J, He Z and Liu B: Epigenetic
mechanism of survivin dysregulation in human cancer. Sci China Life
Sci. 61:808–814. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Chen YK, Hsue SS and Lin LM: Survivin
expression is regulated by an epigenetic mechanism for DMBA-induced
hamster buccal-pouch squamous-cell carcinomas. Arch Oral Biol.
50:593–598. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Hsue SS, Wang WC, Chen YK and Lin LM:
Expression of inhibitors of apoptosis family protein in
7,12-dimethylbenz[a]anthracene-induced hamster buccal-pouch
squamous-cell carcinogenesis is associated with mutant p53
accumulation and epigenetic changes. Int J Exp Pathol. 89:309–320.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Tanaka C, Uzawa K, Shibahara T, Yokoe H,
Noma H and Tanzawa H: Expression of an inhibitor of apoptosis,
survivin, in oral carcinogenesis. J Dent Res. 82:607–611. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Khan Z, Tiwari RP, Mulherkar R, Sah NK,
Prasad GB, Shrivastava BR and Bisen PS: Detection of survivin and
p53 in human oral cancer: Correlation with clinicopathologic
findings. Head Neck. 31:1039–1048. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Ikuta M, Podyma KA, Maruyama K, Enomoto S
and Yanagishita M: Expression of heparanase in oral cancer cell
lines and oral cancer tissues. Oral Oncol. 37:177–184. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Michi Y, Morita I, Amagasa T and Murota S:
Human oral squamous cell carcinoma cell lines promote angiogenesis
via expression of vascular endothelial growth factor and
upregulation of KDR/flk-1 expression in endothelial cells. Oral
Oncol. 36:81–88. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Gioanni J, Fischel JL, Lambert JC, Demard
F, Mazeau C, Zanghellini E, Ettore F, Formento P, Chauvel P,
Lalanne CM and Courdi A: Two new human tumor cell lines derived
from squamous cell carcinomas of the tongue: Establishment,
characterization and response to cytotoxic treatment. Eur J Cancer
Clin Oncol. 24:1445–1455. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
de Maria S, Lo Muzio L, Braca A, Rega P,
Cassano A, Vinella A, Fumarulo R, Serpico R, Farina E, Metafora V,
et al: Survivin promoter-31G/C polymorphism in oral cancer cell
lines. Oncol Lett. 2:935–939. 2011.PubMed/NCBI
|
|
83
|
Chou J, Lin YC, Kim J, You L, Xu Z, He B
and Jablons DM: Nasopharyngeal carcinoma-review of the molecular
mechanisms of tumorigenesis. Head Neck. 30:946–963. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Altieri DC: Survivin-The inconvenient IAP.
Semin Cell Dev Biol. 39:91–96. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Altieri DC: Survivin and IAP proteins in
cell-death mechanisms. Biochem J. 430:199–205. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Chen X, Duan N, Zhang C and Zhang W:
Survivin and tumorigenesis: Molecular mechanisms and therapeutic
strategies. J Cancer. 7:314–323. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Kanwar JR, Kamalapuram SK and Kanwar RK:
Targeting survivin in cancer: The cell-signalling perspective. Drug
Discov Today. 16:485–494. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Wang X, Beitler JJ, Huang W, Chen G, Qian
G, Magliocca K, Patel MR, Chen AY, Zhang J, Nannapaneni S, et al:
Honokiol Radiosensitizes squamous cell carcinoma of the head and
neck by downregulation of survivin. Clin Cancer Res. 24:858–869.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Hu J, Pan J, Luo Z and Tao Z:
Downregulation of survivin by shRNA inhibits invasion and enhances
the radiosensitivity of laryngeal squamous cell carcinoma. Cell
Biochem Biophys. 72:251–257. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Santarelli A, Mascitti M, Lo Russo L,
Sartini D, Troiano G, Emanuelli M and Lo Muzio L: Survivin-based
treatment strategies for squamous cell carcinoma. Int J Mol Sci.
19(pii): E9712018. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Nakahara T, Kita A, Yamanaka K, Mori M,
Amino N, Takeuchi M, Tominaga F, Kinoyama I, Matsuhisa A, Kudou M
and Sasamata M: Broad spectrum and potent antitumor activities of
YM155, a novel small-molecule survivin suppressant, in a wide
variety of human cancer cell lines and xenograft models. Cancer
Sci. 102:614–621. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Yan X and Su H: YM155 Down-regulates
survivin and induces P53 Up-regulated modulator of apoptosis
(PUMA)-dependent in oral squamous cell carcinoma cells. Med Sci
Monit. 23:1963–1972. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Zhang L, Zhang W, Wang YF, Liu B, Zhang
WF, Zhao YF, Kulkarni AB and Sun ZJ: Dual induction of apoptotic
and autophagic cell death by targeting survivin in head neck
squamous cell carcinoma. Cell Death Dis. 6:e17712015. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Tolcher AW, Mita A, Lewis LD, Garrett CR,
Till E, Daud AI, Patnaik A, Papadopoulos K, Takimoto C, Bartels P,
et al: Phase I and pharmacokinetic study of YM155, a small-molecule
inhibitor of survivin. J Clin Oncol. 26:5198–5203. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Satoh T, Okamoto I, Miyazaki M, Morinaga
R, Tsuya A, Hasegawa Y, Terashima M, Ueda S, Fukuoka M, Ariyoshi Y,
et al: Phase I study of YM155, a novel survivin suppressant, in
patients with advanced solid tumors. Clin Cancer Res. 15:3872–3880.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Giaccone G, Zatloukal P, Roubec J, Floor
K, Musil J, Kuta M, van Klaveren RJ, Chaudhary S, Gunther A and
Shamsili S: Multicenter phase II trial of YM155, a small-molecule
suppressor of survivin, in patients with advanced, refractory,
non-small-cell lung cancer. J Clin Oncol. 27:4481–4486. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Kelly RJ, Thomas A, Rajan A, Chun G,
Lopez-Chavez A, Szabo E, Spencer S, Carter CA, Guha U, Khozin S, et
al: A phase I/II study of sepantronium bromide (YM155, survivin
suppressor) with paclitaxel and carboplatin in patients with
advanced non-small-cell lung cancer. Ann Oncol. 24:2601–2606. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Gurpinar E, Grizzle WE and Piazza GA:
NSAIDs inhibit tumorigenesis, but how? Clin Cancer Res.
20:1104–1113. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Tinsley HN, Grizzle WE, Abadi A, Keeton A,
Zhu B, Xi Y and Piazza GA: New NSAID targets and derivatives for
colorectal cancer chemoprevention. Recent Results Cancer Res.
191:105–120. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Sato A, Mizobuchi Y, Nakajima K, Shono K,
Fujihara T, Kageji T, Kitazato K, Matsuzaki K, Mure H, Kuwayama K,
et al: Blocking COX-2 induces apoptosis and inhibits cell
proliferation via the Akt/survivin- and Akt/ID3 pathway in
low-grade-glioma. J Neurooncol. 132:231–238. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Scheper MA, Nikitakis NG, Chaisuparat R,
Montaner S and Sauk JJ: Sulindac induces apoptosis and inhibits
tumor growth in vivo in head and neck squamous cell carcinoma.
Neoplasia. 9:192–199. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Chiou SK and Mandayam S: NSAIDs enhance
proteasomic degradation of survivin, a mechanism of gastric
epithelial cell injury and apoptosis. Biochem Pharmacol.
74:1485–1495. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Chiou SK, Hoa N, Hodges A, Ge L and Jadus
MR: Indomethacin promotes apoptosis in gastric cancer cells through
concomitant degradation of Survivin and Aurora B kinase proteins.
Apoptosis. 19:1378–1388. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Olie RA, Simões-Wüst AP, Baumann B, Leech
SH, Fabbro D, Stahel RA and Zangemeister-Wittke U: A novel
antisense oligonucleotide targeting survivin expression induces
apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer
Res. 60:2805–2809. 2000.PubMed/NCBI
|
|
105
|
Talbot DC, Ranson M, Davies J, Lahn M,
Callies S, André V, Kadam S, Burgess M, Slapak C, Olsen AL, et al:
Tumor survivin is downregulated by the antisense oligonucleotide
LY2181308: A proof-of-concept, first-in-human dose study. Clin
Cancer Res. 16:6150–6158. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Hansen JB, Fisker N, Westergaard M,
Kjaerulff LS, Hansen HF, Thrue CA, Rosenbohm C, Wissenbach M, Orum
H and Koch T: SPC3042: A proapoptotic survivin inhibitor. Mol
Cancer Ther. 7:2736–2745. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Sapra P, Wang M, Bandaru R, Zhao H,
Greenberger LM and Horak ID: Down-modulation of survivin expression
and inhibition of tumor growth in vivo by EZN-3042, a locked
nucleic acid antisense oligonucleotide. Nucleosides Nucleotides
Nucleic Acids. 29:97–112. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Carrasco RA, Stamm NB, Marcusson E,
Sandusky G, Iversen P and Patel BK: Antisense inhibition of
survivin expression as a cancer therapeutic. Mol Cancer Ther.
10:221–232. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Kojima H, Iida M, Yaguchi Y, Suzuki R,
Hayashi N, Moriyama H and Manome Y: Enhancement of Cisplatin
sensitivity in squamous cell carcinoma of the head and neck
transfected with a survivin antisense gene. Arch Otolaryngol Head
Neck Surg. 132:682–685. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Tanioka M, Nokihara H, Yamamoto N, Yamada
Y, Yamada K, Goto Y, Fujimoto T, Sekiguchi R and Uenaka K: Phase I
study of LY2181308, an antisense oligonucleotide against survivin,
in patients with advanced solid tumors. Cancer Chemother Pharmacol.
68:505–511. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Schmidt SM, Schag K, Müller MR, Weck MM,
Appel S, Kanz L, Grünebach F and Brossart P: Survivin is a shared
tumor-associated antigen expressed in a broad variety of
malignancies and recognized by specific cytotoxic T cells. Blood.
102:571–576. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Schmitz M, Diestelkoetter P, Weigle B,
Schmachtenberg F, Stevanovic S, Ockert D, Rammensee HG and Rieber
EP: Generation of survivin-specific CD8+ T effector cells by
dendritic cells pulsed with protein or selected peptides. Cancer
Res. 60:4845–4849. 2000.PubMed/NCBI
|
|
113
|
Miyazaki A, Kobayashi J, Torigoe T,
Hirohashi Y, Yamamoto T, Yamaguchi A, Asanuma H, Takahashi A,
Michifuri Y, Nakamori K, et al: Phase I clinical trial of
survivin-derived peptide vaccine therapy for patients with advanced
or recurrent oral cancer. Cancer Sci. 102:324–329. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Hirohashi Y, Torigoe T, Maeda A, Nabeta Y,
Kamiguchi K, Sato T, Yoda J, Ikeda H, Hirata K, Yamanaka N and Sato
N: An HLA-A24-restricted cytotoxic T lymphocyte epitope of a
tumor-associated protein, survivin. Clin Cancer Res. 8:1731–1739.
2002.PubMed/NCBI
|
|
115
|
Idenoue S, Hirohashi Y, Torigoe T, Sato Y,
Tamura Y, Hariu H, Yamamoto M, Kurotaki T, Tsuruma T, Asanuma H, et
al: A potent immunogenic general cancer vaccine that targets
survivin, an inhibitor of apoptosis proteins. Clin Cancer Res.
11:1474–1482. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Liu Z, Wang T, Zhang Z, Tang S, Feng S,
Yue M, Hu M, Xuan L and Chen Y: Survivin downregulation using siRNA
nanoliposomes inhibits cell proliferation and promotes the
apoptosis of MHCC-97H hepatic cancer cells: An in vitro and
in vivo study. Oncol Lett. 13:2723–2730. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Zhang Z, Wang T, Liu Z, Tang S, Yue M,
Feng S, Hu M, Xuan L and Chen Y: Small interfering RNA targeting of
the survivin gene inhibits human tumor cell growth in vitro.
Exp Ther Med. 14:35–42. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Li Y, Liu D, Zhou Y, Li Y, Xie J, Lee RJ,
Cai Y and Teng L: Silencing of survivin expression leads to reduced
proliferation and cell cycle arrest in cancer cells. J Cancer.
6:1187–1194. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Xu JH, Wang AX, Huang HZ, Wang JG, Pan CB
and Zhang B: Survivin shRNA induces caspase-3-dependent apoptosis
and enhances cisplatin sensitivity in squamous cell carcinoma of
the tongue. Oncol Res. 18:377–385. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Chen XM, Luan XY, Lei DP, Ma XJ, Liu XX,
Liu J and Pan XL: Suppression of survivin expression by short
hairpin RNA induces apoptosis in human laryngeal carcinoma cells.
ORL J Otorhinolaryngol Relat Spec. 70:168–175. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Wang Y, Zhu H, Quan L, Zhou C, Bai J,
Zhang G, Zhan Q and Xu N: Downregulation of survivin by RNAi
inhibits the growth of esophageal carcinoma cells. Cancer Biol
Ther. 4:974–978. 2005. View Article : Google Scholar : PubMed/NCBI
|
